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Abstract
Purpose Compartmental modelling of 3′-deoxy-3′-[
18F]-
fluorothymidine (
18F-FLT) PET-derived kinetics provides
a method for noninvasive assessment of the proliferation
rate of gliomas. Such analyses, however, require an input
function generally derived by serial blood sampling and
counting. In the current study,
18F-FLT kinetic parameters
obtained from image-derived input functions were com-
pared with those from input functions derived from
arterialized blood samples.
Methods Based on the analysis of 11 patients with glioma
(WHO grade II–IV) a procedure for the automated
extraction of an input function from
18F-FLT brain PET
data was derived. The time–activity curve of the volume of
interest with the maximum difference in
18F-FLT uptake
during the first 5 min after injection and the period from 60
to 90 min was corrected for partial-volume effects and in
vivo metabolism of
18F-FLT. For each patient a two-
compartment kinetic model was applied to the tumour
tissue using the image-derived input function. The resulting
kinetic rate constants K1 (transport across the blood–brain
barrier) and Ki (metabolic rate constant or net influx
constant) were compared with those obtained from the
same data using the input function derived from blood
samples. Additionally, the metabolic rate constant was
correlated with the frequency of tumour cells stained with
Ki-67, a widely used immunohistochemical marker of cell
proliferation.
Results The rate constants from kinetic modelling were
comparable when the blood sample-derived input functions
were replaced by the image-derived functions (K1,img and
K1,sample, r=0.95, p<10
−5;K i,img and Ki,sample, r=0.86, p<
0.001). A paired t-test showed no significant differences in
the parameters derived with the two methods (K1,img and
K1,sample, p=0.20; Ki,img and Ki,sample, p=0.92). Further-
more, a significant correlation between Ki,img and the
percentage of Ki-67-positive cells was observed (r=0.73,
p=0.01).
Conclusion Kinetic modelling of
18F-FLT brain PET data
using image-derived input functions extracted from human
brain PET data with the practical procedure described here
provides information about the proliferative activity of
brain tumours which might have clinical relevance espe-
cially for monitoring of therapy response in future clinical
trials.
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Introduction
Positron emission tomography (PET) is a powerful method
for the noninvasive measurement of metabolic processes in
vivo. Such measurements are performed by kinetic analysis,
which requires, in addition to the tissue time–activity curve
(TAC), the arterial input function (IF; the amount of tracer
in blood plasma as a function of time). While the TAC is
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DOI 10.1007/s00259-009-1244-4easily obtained from the PET data by dividing the scan time
into several time frames, the arterial IF is commonly
determined from blood samples taken during the PET scan.
The direct determination of the IF via blood samples is
laborious, introduces a potential source of errors, and
quantification of PET data acquired without simultaneous
blood sampling is not possible. Noninvasive methods have
been developed for the extraction of IFs from PET data, for
example by placing a region of interest on vascular
structures within the field of view (FOV) such as the left
ventricle of the heart or the aorta [1–8]. It has been shown
that the image-derived IF act as a good substitute for the
arterial IF and kinetic constants can be reproduced.
However, in human brain PET images these large vascular
structures are outside the FOV and smaller vessels have to
be taken into account. An alternative approach consists of
the estimation of an IF from a population-based arterial IF
[9, 10]. These methods are minimally invasive since they
require at least one blood sample for scaling. Recently,
another minimally invasive method consisting of a cluster
analysis of TACs and requiring three venous blood samples
for the determination of an IF for [
18F]-2-deoxy-2-fluoro-D-
glucose (
18F-FDG) human brain PET was presented [11].
Factor analysis of PET-derived time–activity data has also
been used for extraction of the IF and quantification of
pertinent kinetic parameters [12].
Thymidine is the only nucleoside that is incorporated
exclusively into DNA but not into RNA and is therefore a
good candidate for measuring cellular proliferation. Its
phosphorylation occurs by two pathways: the salvage
pathway via thymidine kinase (TK1) and the de novo
pathway via thymidylate synthase (TS) [13]. For a number
of tumour cell lines it has been shown that TK1 activity
exceeds TS activity by a factor of at least 16 [14]. 3′-
Deoxy-3′-[
18F]-fluorothymidine (
18F-FLT), an analogue of
thymidine, is a selective substrate for TK1, that is for the
salvage pathway. TK1 catalyses the phosphorylation of
18F-FLT to
18F-FLT-monophosphate, which is further
phosphorylated to
18F-FLT-diphosphate and
18F-FLT-
triphosphate. TK1 activity is proportional to the rates of
DNA replication and cell proliferation in tumour [15–18].
Therefore, cellular proliferation can be assessed by
18F-FLT
although
18F-FLT, in contrast to thymidine, is effectively
not incorporated into DNA [19, 20]. The kinetics of
18F-FLT are qualitatively similar to those of
18F-FDG, with
a two-tissue compartment model applicable to both tracers.
Like phosphorylated
18F-FDG,
18F-FLT is trapped within
the cell. i.e. the rate constant for dephosphorylation, k4,i s
small compared to the other rate constants, but not
negligible in the model [21, 22].
We present a simple and practical method for extracting
IFs from
18F-FLT PET data in the human brain. The rate
constants resulting from kinetic modelling of
18F-FLT PET
data from patients with high-grade glioma using the image-
derived IFs are compared with those derived using IFs from
arterialized blood samples. Our results are further validated
by correlation of the metabolic rate constant with the
percentage of cells positive in Ki-67 immunostaining of
tumour tissue.
Materials and methods
PET scan, patients, samples
We used the same dataset as used in our previous study in
order to investigate the potential of the image-derived IF to
reproduce the results obtained with IFs from blood samples
(cf. [20]). Two patients from the previous study were
excluded from this analysis because they lacked Ki-67
staining.
In brief, 11 patients with newly diagnosed high-grade
glioma were investigated with
18F-FLT PET. PET imaging
was performed on an ECAT EXACT scanner (CTI,
Siemens; one patient) or an ECAT EXACT HR scanner
(CTI, Siemens; ten patients). After a 10-min transmission
scan with a
68Ge/
68Ga source, emission data were acquired
for 90 min. The tracer was injected at the beginning of the
emission scan. Arterialized blood samples were taken from
the heated dorsal hand vein [23, 24]. Oxygen saturation was
not measured in patients 1, 2, 3, and 10. In the other
patients it was above 80% (minimum 82%, maximum 95%,
mean 89%). The PET scan time was divided into time
frames of 6×10 s, 3×20 s, 2×30 s, 2×60 s, 2×150 s, and
16×300 s. For the kinetic analysis of the data, a TAC was
taken from an 8-mm diameter circular region of interest
placed over the tumour region with the maximum tracer
accumulation during the 90-min scan time.
Histology
PET-guided tumour tissue probes at the location of
maximum tracer accumulation were taken by stereotactic
biopsy (seven patients) or by resection (four patients).
Staining was performed with MIB-1 (Ki-67) antibody using
the avidin-biotin-peroxidase complex (ABC) method and
the DCS detection kit with DAB and H2O2 (DCS,
Hamburg, Germany). All cells with nuclear staining of
any intensity were regarded as positive. Proliferative
activity was defined as the percentage of nuclei stained
with MIB-1 per total number of nuclei in the biopsy.
The percentage of Ki-67-positive cells was determined in
the four microscopic high-power fields (0.16 mm
2) with the
maximum fraction of labelled cells.
The metabolic rate constants derived from kinetic
analysis of
18F-FLT PET were compared with proliferation
Eur J Nucl Med Mol Imaging (2009) 36:1960–1967 1961rates determined via Ki-67 staining of tumour tissue. The
IFs for the kinetic analysis were obtained from blood
samples taken during the PET scan. For a detailed
description of the methods see Ullrich et al. [20].
Extraction of the IF from PET data
Compared to a usual TAC an IF resulting from a bolus
injection has special characteristics, namely a distinct
peak in the first minute after injection (this is when the
bolus is transported through the vascular system) and a
low slowly decreasing activity at late scan times. Based
on these characteristic features, an automated algorithm
was developed for extracting the
18F-FLT IF from the
dynamic PET: the location of a suitable blood TAC was
defined by the volume of interest (VOI, 6.6×6.6×
9.3 mm
3) with the maximum difference between the mean
a c t i v i t yd u r i n gt h ef i r s t5m i na f t e ri n j e c t i o na n dt h em e a n
a c t i v i t yf r o m6 0t o9 0m i n .S i n c et h ev o l u m eo ft h eV O I
was larger than the spatial resolution of the PET scanners
used, the parameters for partial volume correction were
independent of the scanner type. As shown in Fig. 1a, the
‘raw’ IFs thus obtained had the characteristic appearance
of a typical IF.
Corrections of the raw IF
Simplified partial-volume correction
In order to correct the raw IF for partial-volume effects a
simplified correction was applied. The VOI, from which the
IF was extracted, was only partially covered by a blood
vessel and partially by surrounding tissue. Furthermore, in
the PET data the difference between the vessel and
surrounding tissue decreased over time, i.e. the amount of
activity in the blood vessel decreased due to the distribution
of the tracer in the compartments while the surrounding
activity increased to amounts that could not be explained by
vascular structures. In order to take into account this
observation we assumed that there was transport from
vessel to surrounding tissue by passive diffusion. If av is the
fractional volume of the vessel and k is the constant for the
transport to the surrounding tissue, the background con-
centration Cbg is given by Cbg(t) = (1 − exp(−kt)) Creal(t)
and the measured concentration is Cm(t) = av Creal(t) +
(1−av)C bg(t). The real intravascular concentration Creal can
then be obtained from the measured concentration Cm by:
CrealðtÞ¼
1
av þ 1   av ðÞ 1   e kt ðÞ
CmðtÞ: ð1Þ
In this case the partial-volume correction is 1/av at the
beginning of the scan time while it decreases to 1 at late
times when the activity in the vessel is similar to the
background activity of the surrounding tissue.
Equation 1 was applied to the data using a transport rate k
of 0.01, 0.1 and 1.0 min
−1 and a partial volume of the vessel
av of 1 (this is equivalent to no partial-volume effect), 0.8
and 0.6 in order to test the sensitivity of the kinetic
parameters as response to the partial-volume correction.
Glucuronidation
When
18F-FLT is circulating through the organism it is
glucuronidated in the liver [25]. This radioactive metabolite
is not transported from plasma into brain tissue. Shields et
al. reported a contribution of
18F-FLT to the total plasma
0 20 40 60 80
Time (min)
0
50
100
150
200
250
S
p
e
c
.
 
A
c
t
.
 
(
k
B
q
/
c
c
)
 
0 2 4 6 8 10
0
50
100
150
200
250 corrected image derived IF
raw image derived IF
sample IF
1.2
1
0.8
0.6
0.4
0.2
0
A
U
C
(
i
m
g
,
t
)
/
A
U
C
(
s
m
p
l
,
t
=
9
0
)
AUC(smpl,t)/AUC(smpl,t=90)
0 0.2 0.4 0.6 0.8 1
a
b
Fig. 1 a Input functions: example IF from blood samples (sample IF),
the corresponding raw image-derived IF (raw image derived IF) and
the partial-volume effect- and metabolite-corrected IF (corrected
image derived IF). b Correlation between sample-derived and
corrected image-derived IF. Data points show the time integrals
(AUC) and standard deviations of the image-derived and the sample-
derived IFs at 0.3, 0.5, 1, 2, 5, 10, 25, 50, 75 and 90 min after
injection normalized by the time integral of the sample-derived IF
over the entire scanning time of 90 min. The error bars for the sample-
derived AUCs show the variation of the sample-derived IFs; for
example, at 25 min the mean AUC was 0.56 (±0.03)
1962 Eur J Nucl Med Mol Imaging (2009) 36:1960–1967activity of 82% at 30 min and 74% at 60 min after injection
[26]. A similar fraction has been reported by Visvikis et al.
(69% at 60 min after injection) [25]. Assuming a mono-
exponential decrease in nonmetabolized
18F-FLT in plasma,
this corresponds to an average time scale of Tgluc <170 min
for this process. After the partial-volume correction
described above the fraction of activity attributable to
18F-
FLTwas obtained by multiplying by the factor exp(−t/Tgluc)
where t is the time after injection (in minutes).
Timing
In the ideal case the bolus of the tracer is injected simulta-
neously with the start of the PET scan. The accuracy of this
procedure depends on several factors such as the injector, the
patient, correct synchronization of clocks, etc. In order to
correctforpotentialtiming differences the bloodcurve obtained
from the PET data was extrapolated to determine the offset of
the true injection time with respect to the start time of the PET
scan. Note that there was no time offset between the image-
derived blood curve and the TACs because they originated
from the same data. But the injection time point is important for
the application of the corrections for partial-volume effect and
for blood levels of the glucuronidation metabolite. The time in
Eq. 1 is then relative to the injection time, i.e. t = tPET − tinj
(tPET is the time relative to the start of the PET scan, and tinj is
the time of injection relative to the start of the PET scan).
Assuming a linear increase in the IF immediately after injec-
tion, tinj is given by the intercept of the line fitted to the first
data points of the image-derived raw IF with the time axis.
Kinetic modelling
The kinetics of
18F-FLT in tumour tissue are best described
by a two-compartment model corresponding to free and
phosphorylated tracer, respectively, with the blood-borne
activity accounted for by the IF [21]. The model includes
five free parameters: the transport parameters K1 (transport
from blood across the blood–brain barrier into the tissue),
k2 (transport from tissue to blood), k3 (phosphorylation by
Tk1), k4 (dephosphorylation), and vB (the fraction of blood
volume in the tissue). In analogy to
18F-FLT, the salvage
pathway of thymidine is characterized by the rate constants
KTh1 … kTh4. Since thymidine—in contrast to
18F-FLT—is
incorporated into DNA, there is an additional rate constant
for thymidine describing its incorporation into DNA, kDNA.
Proliferation is proportional to the rate of incorporation of
thymidine into DNA and can be expressed as:
P  
KTh1   kTh3
1 þ kTh4=kDNA ðÞ   kTh2 þ kTh3
  ThB ð2Þ
where ThB is the thymidine concentration in blood plasma.
In tumour tissue the dephosphorylation rate is small
compared to the rate of incorporation of thymidine into
DNA , kTh4<<kDNA. In this case the term in parentheses in
the denominator of Eq. 2 reduces to 1 and the expression
for the proliferation rate becomes independent of kDNA.
Thus, the proliferation rate constant can be expressed in
terms of the rate constants of
18F-FLT, although
18F-FLT in
contrast to thymidine is not incorporated into DNA.
Proliferation is then proportional to Ki =K 1 ×k 3/
(k2 +k 3)[ 20]. The parameters were calculated using the
commercial software PMOD (PMOD Technologies, version
2.85).
Results
Location of IF in PET images
In all cases the automatic procedure for finding the region
suitable for extraction of a blood curve provided raw
IFs, which showed the characteristic patterns of an IF
(Fig. 1a). Visual inspection of the PET images and
coregistered Gd-enhanced T1-weighted MR images
revealed that the regions were localized within venous
blood vessels. In 2 of the 11 subjects the procedure
selected the confluens sinuum while in the remaining 9
subjects the sinus cavernosus was selected. Although the
carotid artery could also be identified in the PET image
with the help of the coregistered MR image (Fig. 2), the
venous blood pools better fulfilled the criteria of an “ideal”
IF (see Discussion).
Partial-volume correction
In order to determine the best set of parameters for a
simplified partial-volume correction, different sets of
parameters were applied to Eq. 1. From these corrected
IFs the kinetic parameters of the tumour tissue were
calculated; Table 1 shows the results. A fractional vessel
volume av of 0.8 and a transport constant k of 0.1 min
−1
provided the best correlation with the in vitro proliferation
marker Ki-67 (r=0.73, p=0.01). All tested combinations of
parameters displayed in the Table 1 showed significant
correlations (p<0.05).
Correlation of image- and sample-derived IFs
In order to compare the image- and the sample-derived IFs
we calculated the time integrals (AUC) of the IFs at
different time points and normalized them in relation to the
time integral over the entire scan time (90 min) of the
sample-derived IF (Fig. 1b). The mean normalized AUC of
the image-derived IFs at 90 min was 1.02 (±0.28).
Eur J Nucl Med Mol Imaging (2009) 36:1960–1967 1963Modelling results
Kinetic modelling provides the kinetic parameters of
18F-
FLT (Table 2). The most relevant of them are: the transport
of tracer (and of its endogenous analogue thymidine) across
the blood–brain barrier represented by the constant K1 and
the metabolic rate constant of
18F-FLT (Ki) reflecting
cellular proliferation. In the following the parameters
obtained with the IF from blood samples are labelled with
sample and those using the image-derived IFs are labelled
with img. In order to investigate the effect of replacing the
IFs measured from blood samples by the image-derived IFs
Fig. 2 Location of the blood
TAC. The blood TAC is located
at either the confluens sinuum
(a) or the sinus cavernosus (b)
in the Gd-enhanced T1-
weighted MR images (top) and
in the summed
18F-FLT PET
images (bottom). The white
arrows in b mark the carotid
artery visible in both the MR
and PET images
Table 1 Correlation between Ki and Ki-67 using different parameters
for the partial-volume correction. Values are correlation coefficients, r
(all correlations are significant, p<0.05)
Fractional vessel volume (av) Transport constant (k,min
−1)
0.01 0.1 1.0
1.0 0.69 0.69 0.69
0.8 0.66 0.73 0.62
0.6 0.67 0.70 0.69
1964 Eur J Nucl Med Mol Imaging (2009) 36:1960–1967obtained with the method described here on the modelling
results we calculated three correlations: (1) between K1,img
and K1,sample (r=0.95, p<10
−5), (2) between Ki,img and
Ki,sample (r=0.86, p<0.001), and (3) between Ki,img and the
percentage of Ki-67-positive cells (r=0.73, p=0.01). The
correlation between Ki,sample and Ki-67 immunostaining
was r=0.79, p=0.004 [20]. The values are plotted in Fig. 3.
The FLT standardized uptake value (SUV) was not
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Eur J Nucl Med Mol Imaging (2009) 36:1960–1967 1965significantly correlated with the percentage of Ki-67-
positive cells (r=0.57, p=0.07) [20].
A paired t-test showed no significant differences in the
parameters derived by the two methods (K1,img and
K1,sample, p=0.20; Ki,img and Ki,sample, p=0.92).
Discussion
In this study we demonstrated that the rate constants
provided by kinetic analysis of
18F-FLT brain PET data in
high-grade glioma using an IF derived from blood samples
measured during the PET scan can be reproduced if the
measured IF is replaced by an IF extracted from the PET
data. The respective values of the physiologically important
rate constants, K1 and Ki, were comparable for these two
different approaches to measurement of the IFs. The
calculated metabolic rate constant, Ki,img, was correlated
significantly with the percentage of Ki-67-positive cells, a
standard immunohistochemical marker of cell proliferation.
The described procedure for the extraction of the IF from
PET data involved three steps: (1) extraction of the raw IF, (2)
simplified correction for partial-volume effect, and (3) correc-
t i o nf o ri nv i v om e t a b o l i s mo f
18F-FLT (glucuronidation). The
processes were quite simple and can therefore be easily
implemented in the routine clinical setting. Even if the step of
partial-volume correction was omitted, the resulting Ki,img
was still correlated significantly with the in vitro proliferation
marker Ki-67 (r=0.69, p=0.02, see Table 1), indicating that
partial-volume correction is not a critical issue here.
The coregistered MR images revealed that the raw-IF
region was localized within the venous blood pool (con-
fluens sinuum or sinus cavernosus) rather than within the
arterial blood pool. Actually the arterial blood pool should
provide a more accurate IF. In order to examine the
difference we manually extracted the TACs from the carotid
artery. Presumably due to the small size of the artery and
therefore its greater sensitivity for patient motion, these raw
IFs were very noisy and most of them could not be used for
kinetic modelling. Thus, we conclude that, although
preferred from a theoretical point of view, the intracranial
cerebral arteries are not a suitable source in human brain
PET data for the extraction of the IF.
Comparison of the peak time in the TACs from the artery
with the peak time of the image-derived IFs from the
described venous blood pool showed good agreement. The
differences were below the temporal resolution of the early
dynamic PET data, i.e. <10 s. In order to get the correct
peak time for the IF from arterialized blood samples, a
manual correction has to be applied. Arterialized blood
samples are usually taken from the hand and the arrival
time of the bolus in the hand differs from the arrival time in
the brain by about 7 s [27]. The manual correction by a
mean delay time introduces a potential source of error
because this time difference is variable. Comparison of the
peak location in image-derived IFs and the sample-derived
IFs revealed a time delay that is even higher than the
reported one and had a large standard deviation (24±16 s).
Nevertheless, taking blood samples directly from the artery
is invasive, painful and laborious and therefore the use of
arterialized blood samples as surrogate for arterial blood
samples has become part of clinical routine.
In comparison to a sample-derived IF an image-derived
IF has important advantages: it is noninvasive, and it does
not require any additional handling and measurements apart
from the PET scan itself. Since all the data are acquired
within the same system there is no cross-calibration needed
(e.g. between the PET scanner and well counter), eliminat-
ing this possible source of error. Also no time offset needs
to be determined since the only relevant reference time is
that of the PET scan. The time of injection can be extracted
from the PET data (see Materials and methods section).
Conclusion
Image-derived IFs represent an accurate, clinically practi-
cal, and convenient surrogate for blood sample-derived IFs
for kinetic modelling of
18F-FLT data in patients with brain
tumours. Whether our findings can be substantiated in a
larger patient series has to be demonstrated in future trials.
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